Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules
Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules (Cancer Or Benign Endoscopy) (KOBE)
University Hospital, Toulouse
60 participants
Apr 8, 2022
INTERVENTIONAL
Conditions
Summary
Lung cancer screening is based on low dose CT scan (LDCT), a highly sensitive but poorly specific tool. Complementary specific approaches are thus strongly needed, among which cell-free DNA (cfDNA) genotyping has been proven highly specific but of low sensitivity (25 to 50% for stage I diseases) due to inconstant tumor shed. Tumor biopsy is thus often required and radial endobronchial ultrasound (rEBUS) bronchoscopy is a minimally invasive approach (\<3% complications) but of limited sensitivity in cases of nodules \< 20 mm. The investigators hypothesized that methylation analysis on cfDNA floating in supernatant derived from rEBUS specimens could improve rEBUS sensitivity
Eligibility
Inclusion Criteria4
- rEBUS bronchoscopy planned for one, two or three ≤ 20 mm nodule
- World Health Organization (WHO) Performance status 0-3
- Informed signed consent
- Patient affiliated or beneficiary of a social security scheme (Social Security or Universal Medical Coverage).
Exclusion Criteria4
- Lung cancer diagnosed before the date of the procedure
- Lung cancer strongly suspected due to mediastinal or extra thoracic lesions
- Patient under State Medical Assistance
- Patient deprived of liberty on administrative or judicial decision, or patient under guardianship, curators or safeguard of justice
Interventions
Patients will be taken from an additional blood sample (2 tubes of 7.5 mL of blood = 15 mL) during the preoperative check-up on the day of the ultrasound-bronchoscopy in order to compare the sensitivity of the analysis of free circulating DNA present in the supernatant of pulmonary nodules less than 20 mm samples taken under ultrasound-bronchoscopy to that present in the plasma.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05306912